Top pharma stock to watch: TD Cowen’s pick
TD Cowen identifies Kiniksa Pharmaceuticals (KNSA) as a top pick in the pharma sector, citing strong commercial momentum for Arcalyst and potential value from pipeline candidates. The firm set a $115 price target, noting underpenetrated markets and conservative revenue growth projections. KPL-387, a wholly owned drug, could add $6 to earnings per share by 2027.
How this was made
The 30-second read
Why it matters
Analyst initiation and a $115 target could attract new capital, especially from biotech‑focused funds.
Market read
The coverage may trigger short‑term buying pressure in KNSA and modestly benefit peer biotech stocks.
What to watch
Potential regulatory delays for the pipeline and reliance on a single product line could temper upside.
Background
TD Cowen's new coverage of Kiniksa follows recent sales growth for Arcalyst and upcoming Phase III data for KPL-387.
Ticker impact
TD Cowen initiates coverage of Kiniksa Pharmaceuticals with a $115 price target, citing growth potential for Arcalyst and pipeline candidate KPL-387.
upward pressure as investors price in the bullish outlook and pipeline upside.
The report provides new valuation and growth assumptions not previously disclosed, which can move the stock in the short term.
Market effects
May lift sentiment for the broader pharmaceutical sector as analysts highlight under‑penetrated markets.
U.S. biotech and pharma equities could see modest gains.
Limited to investors focused on U.S. biotech; no broad macro effect.
Counterpoint
The price target may be overly optimistic given execution risk for KPL-387 and competition in IL‑1 antagonists.
Key entities
- companyKiniksa Pharmaceuticals
U.S. biotech developing IL‑1 antagonists.
- research_firmTD Cowen
Equity research boutique issuing the coverage.



